ARID1A and ovarian clear cell cancer: ARID1A have since been observed at high frequency in a number of studies, including uterine and ovarian clear cell carcinoma (46–57%), ovarian endometrioid carcinoma (30%), and uterine endometrioid carcinoma (47–60%) [113,114,115,116].